Evidence map›Paper›PMID 26918946›Full record

ArticlePLoS genetics2016

Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span.

Sandeep Kumar, Nicholas Dietrich, Kerry Kornfeld

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Direct Vascular Effects of Angiotensin II (A Systematic Short Review).International journal of molecular sciences · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Inhibition ofmicroPublication biology · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sandeep KumarDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Nicholas DietrichDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Kerry KornfeldDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Washington University in St. Louis · US

Funding

IDENTIFICATION OF DRUGS THAT DELAY AGINGR01AG026561 · NIA · WASHINGTON UNIVERSITY · PI KORNFELD, KERRY · 2006 to 2017
$3.3M
NIA NIH HHS R01 AG026561NIA NIH HHS R01AG02656106A1
6 · The paper itself

Abstract

Animal aging is characterized by progressive, degenerative changes in many organ systems. Because age-related degeneration is a major contributor to disability and death in humans, treatments that delay age-related degeneration are desirable. However, no drugs that delay normal human aging are currently available. To identify drugs that delay age-related degeneration, we used the powerful Caenorhabditis elegans model system to screen for FDA-approved drugs that can extend the adult lifespan of worms. Here we show that captopril extended mean lifespan. Captopril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure in humans. To explore the mechanism of captopril, we analyzed the acn-1 gene that encodes the C. elegans homolog of ACE. Reducing the activity of acn-1 extended the mean life span. Furthermore, reducing the activity of acn-1 delayed age-related degenerative changes and increased stress resistance, indicating that acn-1 influences aging. Captopril could not further extend the lifespan of animals with reduced acn-1, suggesting they function in the same pathway; we propose that captopril inhibits acn-1 to extend lifespan. To define the relationship with previously characterized longevity pathways, we analyzed mutant animals. The lifespan extension caused by reducing the activity of acn-1 was additive with caloric restriction and mitochondrial insufficiency, and did not require sir-2.1, hsf-1 or rict-1, suggesting that acn-1 functions by a distinct mechanism. The interactions with the insulin/IGF-1 pathway were complex, since the lifespan extensions caused by captopril and reducing acn-1 activity were additive with daf-2 and age-1 but required daf-16. Captopril treatment and reducing acn-1 activity caused similar effects in a wide range of genetic backgrounds, consistent with the model that they act by the same mechanism. These results identify a new drug and a new gene that can extend the lifespan of worms and suggest new therapeutic strategies for addressing age-related degenerative changes.

Indexed as

AgingAngiotensin-Converting Enzyme InhibitorsAnimalsAnimals, Genetically ModifiedCaenorhabditis elegansCaenorhabditis elegans ProteinsCaptoprilElectron Transport Complex IIIForkhead Transcription FactorsLongevityMutationPhosphatidylinositol 3-KinasesReceptor, InsulinRNA InterferenceSirtuinsStress, PhysiologicalACN-1 protein, C elegansAGE-1 protein, C elegansAngiotensin-Converting Enzyme InhibitorsCaenorhabditis elegans ProteinsCaptoprildaf-16 protein, C elegansDAF-2 protein, C elegansElectron Transport Complex IIIForkhead Transcription FactorsIsp-1 protein, Caenorhabditis elegansPhosphatidylinositol 3-KinasesReceptor, InsulinSIR-2.1 protein, C elegansSirtuins

Identifiers

PMID26918946
PMCPMC4769152
OpenAlexW2289764069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.